anidulafungin (eraxis) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Anidulafungin (brand names Eraxis (in U.S. and Russia) and Ecalta (in Europe)) is a semi-synthetic echinocandin with antifungal activity and it is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes. This drug is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis; and for the treatment of esophageal candidiasis. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall.   NCATS

Chemistry

  • SMILES: CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)C7=CC=C(O)C=C7)[C@@H](C)O
  • InChIKey: JHVAMHSQVVQIOT-MFAJLEFUSA-N
  • Mol. Mass: 1140.2369
  • ALogP: Missing data
  • ChEMBL Molecule:
    anidulafungin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$22.6200 - $73.8600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(4r,5r)-4,5-dihydroxy-n²-[[4''-(pentyloxy)-p-terphenyl-4-yl]carbonyl]-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline cyclic (6->1)-peptide | anidulafungin | anidulafungina | anidulafungine | anidulafunginum | ecalta | eraxis | ly303366 | ly 303366 | ly-303366 | n-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2r)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide | v-echinocandin

Organizations (20)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (3)


 

Candidemia

Candidiasis (approved 2006)

Peritonitis

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Acute Kidney Injury (Phase 2)

Aspergillosis (Phase 4)

Candida (Phase 3)

Candidemia ()

Candidiasis (Phase 4)

Candidiasis, Invasive (Phase 4)

Central Nervous System Fungal Infections (Phase 4)

Fungemia (Phase 4)

Hematologic Neoplasms (Phase 2)

Infections (Phase 2)

Invasive Fungal Infections (Phase 1)

Invasive Pulmonary Aspergillosis (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Diseases (Phase 4)

Lung Diseases, Fungal (Phase 4)

Mycoses (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1/Phase 2)

Neuroaspergillosis (Phase 3)

Neutropenia (Phase 3)

Obesity (Phase 4)

Obesity, Morbid (Phase 4)

Pneumonia, Ventilator-Associated (Phase 2)

Respiratory Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue